Monopar Therapeutics Inc. vs Mereo BioPharma Group plc — Valuation Comparison 2026
Access all valuation models for MNPR vs MREO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →MREO scores higher with a 5.0/10 quality rating vs MNPR's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Monopar Therapeutics Inc. (MNPR) and Mereo BioPharma Group plc (MREO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
MNPR currently trades at $64.43 with a QOC of 4.3/10, while MREO trades at $0.34 with a QOC of 5.0/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).